UB-612
Vaccine candidate against COVID-19 / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about UB-612?
Summarize this article for a 10 year old
UB-612 is a COVID-19 vaccine candidate developed by United Biomedical Asia [zh], and Vaxxinity, Inc.[1] It is a peptide vaccine.[2][3]
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Peptide subunit |
Clinical data | |
Routes of administration | Intramuscular |
Identifiers | |
DrugBank |
It is composed of SARS-CoV-2 S1-RBD protein and synthetic peptides representing T cell (Th and CTL) epitopes on the nucleocapsid, spike and membrane proteins. The multitope composition is differentiated from other solely spike-protein based vaccines. By recognition against epitopes on Spike (S1-RBD and S2) and non-Spike (N and M) structure proteins, UB-612 provides B-cell and T-cell memory immunity and offers a potential as a universal vaccine to fend off the Omicron variant and new emerging variants of concern.[4][5] Vaxxinity began seeking regulatory approval for UB-612 for use as a booster vaccine in the United Kingdom and Australia in 2022.[6][7]